Roche reported Phase 2 data showing its dual GLP‑1/GIP agonist CT‑388 produced approximately 22.5% placebo‑adjusted weight loss at 48 weeks, prompting the company to progress the asset into Phase 3 development. The data place CT‑388 in the competitive range of leading injectable agents and support Roche’s plan to start pivotal studies by the end of the quarter. The mid‑stage trial enrolled 469 people with obesity and one non‑diabetic comorbidity; Roche tested multiple doses and reported efficacy measures both with and without discontinuation adjustments. Company statements framed the profile as 'competitive' while analysts noted the drug remains years behind market leaders and will face questions on durability, safety, and commercial positioning. Roche acquired CT‑388 via its $2.7 billion buyout of Carmot Therapeutics; the result reflects larger pharma strategies to buy into obesity pipelines. The company will need to define Phase 3 endpoints and potential combination or maintenance strategies to differentiate CT‑388 versus incumbent GLP‑1/GIP medicines. For payors and competitors, the readout renews focus on the crowded obesity market and the commercial calculus for new high‑efficacy incretin combinations.